Chronic Obstructive Pulmonary Disease (COPD)DIVIDENCT07682168
DIVision of the Interlobar Fissure in Patients Who Do Not Respond to Endobronchial Lung Volume Reduction
A study testing Surgical Lung Fissure Division in people with Chronic Obstructive Pulmonary Disease (COPD) and Emphysema, run by Rocco Bilancia.
Trial summary
Surgical division of fissure is hypothesized to be safe and feasible. However, there is no preparatory study to test this hypothesis. It is logically expected that morbidity from the procedure could be less than standard LVRS and in preparation to a side-to-side trial of fissure division versus standard LVRS, a safety… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Lung Volume Reduction Surgery
- What is being tested?
- Surgical Lung Fissure Division
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- No sites listed yet
- Study dates
- Aug 2026to Jan 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age < or equal 75 years
- Stable COPD with less than or equal to 10mg prednisolone daily
- Nonsmoking for 3 months prior to screening and willing to not smoke during the study duration
- Willing and able to complete protocol required study follow-up assessments and procedures
- Fit for thoracoscopy under general anaesthesia (surgical and anaesthetic assessment)
- Recent (< 18 months) endobronchial lung volume reduction (EBLVR) and lack of response defined by:
Show all 9Show fewer
- Persistent symptomatic dyspnoea (mMRC >2) which in the patient's view is no better than baseline
- Absence of target lobar collapse with any residual aeration apparent on imaging
- Persistence of (6a) and (6b) following post procedure StratX CT analysis and revisional bronchoscopy.
Who cannot join
- Fissure completeness <90% on pre EBLVR StratX (i.e less than 10% of fissure to be divided)
- Chartis positive for collateral ventilation or not performed/not satisfactory at initial EBLVR
- Quantitative perfusion of target lobe >25% of total on SPECT assessment.
- Previous lung surgery or pleurodesis on the target side for LVR.
- Clinically significant bronchiectasis -greater than 4 tablespoons mucus per day.
- More than 3 COPD exacerbation episodes in the last year.
Show all 11Show fewer
- Evidence of hypercapnia (pCO2 >7KPa) - ABG to be performed on admission for index procedure
- Clear evidence of pulmonary hypertension (systolic pulmonary arterial pressure >45mmHg) or evidence or right ventricular dysfunction as determined by a recent echocardiogram (<12mo)
- Left ventricular ejection fraction (LVEF) less than 40% as determined by a recent echocardiogram (<12mo)
- Myocardial infarction within 6 months of screening.
- Unable to safely discontinue anticoagulants or platelet activity inhibitors for 7 days.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Surgical division of fissure is hypothesized to be safe and feasible. However, there is no preparatory study to test this hypothesis. It is logically expected that morbidity from the procedure could be less than standard LVRS and in preparation to a side-to-side trial of fissure division versus standard LVRS, a safety and feasibility study is required to test this hypothesis and inform future trial design.
Read the detailed description
- Rationale
Lung volume reduction surgery (LVRS) and Endobronchial lung volume reduction (EBLVR) are both established treatment options for selected patients with symptomatic emphysema. In a randomized trial EBLVR was found to be non-inferior to LVRS in efficacy but uses fewer hospital resources.
Fissure completeness is however necessary for EBLVR to work and this is initially assessed on CT imaging and quantified by a software-based analysis called StratX. If anatomical completeness is less than 80% on StratX, EBLVR cannot be pursued, whereas if fissures are more than 80% complete, further functional assessment with a bronchoscopy and a balloon test called Chartis is required. The presence of a functionally incomplete fissure is called collateral ventilation and precludes EBLVR. If collateral ventilation is absent, EBVs can then be inserted in the target lung lobe.
The intended outcome of the procedure is the achievement of target lobar atelectasis (TLA), leading to reduced hyperinflation and improvement of the dyspnea.
When TLA is not achieved, current best practice is to obtain a CT to check for signs of EBV displacement or paravalvular leak. A further post-procedure StratX is also obtained to identify which valves or airways are affected. A revisional bronchoscopy is then performed to replace/reinsert valves or exclude other causes of malfunctioning such as mucus plugs or granulation tissue formation.
A proportion of patients (up to 20%) will however not show significant TLA despite optimisation or exclusion of EBV malfunctioning at revisional bronchoscopy. When this is the case, surgery in the form of LVRS is the only available treatment for this group of patients. Morbidity from this procedure though is significantly higher, requiring much longer recovery, hospitalization and use of healthcare resources.
The absence of TLA following EBLVR is commonly explained with the appearance of delayed /occult collateral ventilation through an anatomically incomplete fissure despite a favourable initial Chartis assessment..
We hypothesize that this limitation of EBLVR can be addressed by the elimination of collateral ventilation by surgical division of the incomplete interlobar fissure.
Partially complete fissures would also logically require a reduced extent of lung resection and a reduced number of stapled lines compared to LVRS; in addition, given the presence of the already implanted EBVs in the target lobe, this may potentially result in reduced postoperative air leak from resection of fragile lung tissue, hospital stay and complications.
Furthermore, this maneuver is already part of the repertoire of thoracic surgeons as it is required in most lung resection procedures (lobectomy, segmentectomy) for lung cancer.
Fissure division with endobronchial valves in-situ will also allow for intraoperative visual confirmation of target lobe collapse at the end of the procedure with increased chances of volume reduction benefit than can be assumed from EBLVR alone. Operative time may be less or equivalent to LVRS.
In this study, recruitment will be limited to non-responders EBLVR patients. Other causes for lack of response would be excluded prior to recruitment as per routine practice (CT analysis and revisional bronchoscopy). Based on current practice, an average of 3-5 patients per year per centre would be eligible. This safety and feasibility study is therefore designed to include at least 15 treated subjects from 4 UK centres over a period of 18 months. Or 18 months from each site opening to recruitment.
Data collected will inform further larger scale studies in LVR-naïve patients with proven incomplete fissures (concomitant EBV placement and fissure division) and a randomized controlled trial of surgical fissure division + EBV, against standard LVRS.
- Intervention
Thoracoscopic (video assisted or robotic assisted) surgical division of interlobar fissure. Under GA, the patients will be positioned in lateral decubitus. Single lung ventilation. Standard thoracoscopic approach as per individual surgeon preference or practice. Fissure identified and surgical division with mechanical stapler performed.
- Potential risk and benefits
The patients will have already undergone an extensive selection process for EBLVR and an unsuccessful initial EBLVR procedure without clinical benefit.
Having already excluded at revisional bronchoscopy (pre-enrollment in the trial) any malfunctioning or malpositioning of the valves, at the conclusion of the procedure, the intended outcome (target lobar collapse) has a very high probability of being achieved and can be directly visualized and confirmed during thoracoscopy. This may lead up to a 40% improvement in lung function and exercise ability with a consequent durable improvement in quality of life. Further hospital admissions may also be reduced.
We would logically expect morbidity and hospital stay to be less than LVRS, with shorter recovery time and increased chances of achieving the intended outcome. However to demonstrate this, a side-to-side trial of fissure division against standard LVRS would be required. This present study will build the foundations and help inform the design of said trial.
In this study, as the objective is to demonstrate the safety and feasibility of the trial procedure, we want to see and expect to see that morbidity is at least in line with, or less than what expected with standard LVRS, which would be the only other option available for this group of patients.
With standard LVRS, 30-day mortality risk would be up to 3-4%. The most common expected morbidity is protracted air leak requiring drainage with a hospital stay of up to 14 days. Other risks include severe chest infection/exacerbation leading most commonly to type 2 respiratory failure, acute and chronic chest pain, cardiovascular morbidity (DVT-PE, MI, stroke, arrhythmia, heart failure) as well as all other common generic risks related to surgery/general anaesthesia. Risk of conversion to thoracotomy is negligible.
Standard perioperative care will be used.
Currently, in the eligible patient population, the alternatives will therefore be to do nothing and accept ongoing poor condition, or standard LVRS with potential for greater air leak, hospital stay and higher risk of drain-related complications i.e. pain/infection. Rather than a novel procedure, the proposed trial procedure would be an alternative, lesser procedure for patients, utilizing a surgical approach (division of anatomical fissure) that is already in the standard and essential repertoire of thoracic surgeons, being performed by each surgeon in at least 50-100 anatomical lung resection per year.
- Study Hypothesis
The study hypothesis states that it is safe to perform minimally invasive interlobar fissure division in patients who have not responded to prior EBLVR due to occult collateral ventilation. We also hypothesize that it is feasible to recruit the intended number of patients and that complete fissure division, which is the prerequisite to obtain the required target lobe collapse, can be achieved in >90% of the cases. Furthermore, this study will permit future conduct of a prospective randomized comparison of this technique with conventional LVRS.
- Being tested
- Surgical Lung Fissure Division
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Emphysema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Surgical Lung Fissure DivisionProcedure or surgery
Thoracoscopic surgical division of interlobar fissure, in patients who did not achieve Lung Volume Reduction following Endobronchial Valve insertion. Standard thoracoscopic approach under general anaesthetic, as per individual surgeon preference or practice. Fissure identified and surgical division with mechanical stapler performed.
| Study group | Role | What they receive |
|---|---|---|
| Surgical Fissure Division | Other | Surgical Lung Fissure Division in patients who had endobronchial valves for severe emphysema and did not achieve lung volume reduction Receives: Procedure: Surgical Lung Fissure Division |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients recruited
At least 15 patients recruited into the trial over 18 months
Measured: 18 months
Number of patients where surgical division of inter-lobar fissure can be successfully completed
Division of inter-lobar fissure can be completed in 90% of the patients enrolled
Measured: Through study completion (18 months)
Number of patients who experience serious adverse events as a result of the intervention
Number of patients who experience serious adverse events as a result of the intervention
Measured: Through study completion (18 months)
Secondary outcomes (2)
Target lobar collapse
The number of patients achieving target lobar collapse
Measured: Through study completion (18 months)
Costs
The cumulative cost (in GBP) of hospital resources utilised (intraoperative consumables, theatre time, hospital stay, readmission costs)
Measured: Through study completion (18 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jul 2026
- Study startAug 2026 (estimated)
- Primary completionAug 2027 (estimated)
- Study completionJan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Chronic Obstructive Pulmonary Disease (COPD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rocco Bilancia
- Sponsor type
- Other government
- Responsible party
- Sponsor-investigator, Rocco Bilancia, Golden Jubilee National Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07682168
- Sponsor's protocol ID
- 25/CARD/25
- Acronym
- DIVIDE
- Status last verified
- Jun 2026
- First submitted
- 11 Jun 2026
- Last updated
- 2 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Magge A, Kent MS, Ospina-Delgado D, Swenson KE, Parikh MS, Zhang C, Gangadharan SP, Majid A. Robotic-assisted Fissure Completion for Lung Volume Reduction with Endobronchial Valves. Ann Am Thorac Soc. 2022 Dec;19(12):2087-2090. doi: 10.1513/AnnalsATS.202204-308CC. No abstract available.
PubMed 36454166Shafiq M, Polhemus E, Perkins R, Forth V, Marshall MB. Bilateral Bronchoscopic Lung Volume Reduction After Surgical Fissure Completion. Chest. 2022 Aug;162(2):e73-e75. doi: 10.1016/j.chest.2022.02.005.
PubMed 35940665Majid A, Kheir F, Alape D, Chee A, Parikh M, DeVore L, Agnew A, Gangadharan S. Combined Thoracoscopic Surgical Stapling and Endobronchial Valve Placement For Lung Volume Reduction With Incomplete Lobar Fissures: An Experimental Pilot Animal Study. J Bronchology Interv Pulmonol. 2020 Apr;27(2):128-134. doi: 10.1097/LBR.0000000000000617.
PubMed 31436607
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- DIVision of the Interlobar Fissure in Patients Who Do Not Respond to Endobronchial Lung Volume Reduction
- ClinicalTrials.gov ID
- NCT07682168
- Acronym / sponsor ID
- DIVIDE / 25/CARD/25
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Rocco BilanciaOther government
- Study start
- Aug 2026 (estimated)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Jan 2028 (estimated)
- First posted
- 2 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Surgical division of fissure is hypothesized to be safe and feasible. However, there is no preparatory study to test this hypothesis. It is logically expected that morbidity from the procedure could be less than standard LVRS and in preparation to a side-to-side trial of fissure division versus standard LVRS, a safety and feasibility study is required to test this hypothesis and inform future trial design.
Detailed description
- Rationale
Lung volume reduction surgery (LVRS) and Endobronchial lung volume reduction (EBLVR) are both established treatment options for selected patients with symptomatic emphysema. In a randomized trial EBLVR was found to be non-inferior to LVRS in efficacy but uses fewer hospital resources.
Fissure completeness is however necessary for EBLVR to work and this is initially assessed on CT imaging and quantified by a software-based analysis called StratX. If anatomical completeness is less than 80% on StratX, EBLVR cannot be pursued, whereas if fissures are more than 80% complete, further functional assessment with a bronchoscopy and a balloon test called Chartis is required. The presence of a functionally incomplete fissure is called collateral ventilation and precludes EBLVR. If collateral ventilation is absent, EBVs can then be inserted in the target lung lobe.
The intended outcome of the procedure is the achievement of target lobar atelectasis (TLA), leading to reduced hyperinflation and improvement of the dyspnea.
When TLA is not achieved, current best practice is to obtain a CT to check for signs of EBV displacement or paravalvular leak. A further post-procedure StratX is also obtained to identify which valves or airways are affected. A revisional bronchoscopy is then performed to replace/reinsert valves or exclude other causes of malfunctioning such as mucus plugs or granulation tissue formation.
A proportion of patients (up to 20%) will however not show significant TLA despite optimisation or exclusion of EBV malfunctioning at revisional bronchoscopy. When this is the case, surgery in the form of LVRS is the only available treatment for this group of patients. Morbidity from this procedure though is significantly higher, requiring much longer recovery, hospitalization and use of healthcare resources.
The absence of TLA following EBLVR is commonly explained with the appearance of delayed /occult collateral ventilation through an anatomically incomplete fissure despite a favourable initial Chartis assessment..
We hypothesize that this limitation of EBLVR can be addressed by the elimination of collateral ventilation by surgical division of the incomplete interlobar fissure.
Partially complete fissures would also logically require a reduced extent of lung resection and a reduced number of stapled lines compared to LVRS; in addition, given the presence of the already implanted EBVs in the target lobe, this may potentially result in reduced postoperative air leak from resection of fragile lung tissue, hospital stay and complications.
Furthermore, this maneuver is already part of the repertoire of thoracic surgeons as it is required in most lung resection procedures (lobectomy, segmentectomy) for lung cancer.
Fissure division with endobronchial valves in-situ will also allow for intraoperative visual confirmation of target lobe collapse at the end of the procedure with increased chances of volume reduction benefit than can be assumed from EBLVR alone. Operative time may be less or equivalent to LVRS.
In this study, recruitment will be limited to non-responders EBLVR patients. Other causes for lack of response would be excluded prior to recruitment as per routine practice (CT analysis and revisional bronchoscopy). Based on current practice, an average of 3-5 patients per year per centre would be eligible. This safety and feasibility study is therefore designed to include at least 15 treated subjects from 4 UK centres over a period of 18 months. Or 18 months from each site opening to recruitment.
Data collected will inform further larger scale studies in LVR-naïve patients with proven incomplete fissures (concomitant EBV placement and fissure division) and a randomized controlled trial of surgical fissure division + EBV, against standard LVRS.
- Intervention
Thoracoscopic (video assisted or robotic assisted) surgical division of interlobar fissure. Under GA, the patients will be positioned in lateral decubitus. Single lung ventilation. Standard thoracoscopic approach as per individual surgeon preference or practice. Fissure identified and surgical division with mechanical stapler performed.
- Potential risk and benefits
The patients will have already undergone an extensive selection process for EBLVR and an unsuccessful initial EBLVR procedure without clinical benefit.
Having already excluded at revisional bronchoscopy (pre-enrollment in the trial) any malfunctioning or malpositioning of the valves, at the conclusion of the procedure, the intended outcome (target lobar collapse) has a very high probability of being achieved and can be directly visualized and confirmed during thoracoscopy. This may lead up to a 40% improvement in lung function and exercise ability with a consequent durable improvement in quality of life. Further hospital admissions may also be reduced.
We would logically expect morbidity and hospital stay to be less than LVRS, with shorter recovery time and increased chances of achieving the intended outcome. However to demonstrate this, a side-to-side trial of fissure division against standard LVRS would be required. This present study will build the foundations and help inform the design of said trial.
In this study, as the objective is to demonstrate the safety and feasibility of the trial procedure, we want to see and expect to see that morbidity is at least in line with, or less than what expected with standard LVRS, which would be the only other option available for this group of patients.
With standard LVRS, 30-day mortality risk would be up to 3-4%. The most common expected morbidity is protracted air leak requiring drainage with a hospital stay of up to 14 days. Other risks include severe chest infection/exacerbation leading most commonly to type 2 respiratory failure, acute and chronic chest pain, cardiovascular morbidity (DVT-PE, MI, stroke, arrhythmia, heart failure) as well as all other common generic risks related to surgery/general anaesthesia. Risk of conversion to thoracotomy is negligible.
Standard perioperative care will be used.
Currently, in the eligible patient population, the alternatives will therefore be to do nothing and accept ongoing poor condition, or standard LVRS with potential for greater air leak, hospital stay and higher risk of drain-related complications i.e. pain/infection. Rather than a novel procedure, the proposed trial procedure would be an alternative, lesser procedure for patients, utilizing a surgical approach (division of anatomical fissure) that is already in the standard and essential repertoire of thoracic surgeons, being performed by each surgeon in at least 50-100 anatomical lung resection per year.
- Study Hypothesis
The study hypothesis states that it is safe to perform minimally invasive interlobar fissure division in patients who have not responded to prior EBLVR due to occult collateral ventilation. We also hypothesize that it is feasible to recruit the intended number of patients and that complete fissure division, which is the prerequisite to obtain the required target lobe collapse, can be achieved in >90% of the cases. Furthermore, this study will permit future conduct of a prospective randomized comparison of this technique with conventional LVRS.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Surgical Fissure Division | Other | Procedure: Surgical Lung Fissure DivisionSurgical Lung Fissure Division in patients who had endobronchial valves for severe emphysema and did not achieve lung volume reduction |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Age < or equal 75 years
- Stable COPD with less than or equal to 10mg prednisolone daily
- Nonsmoking for 3 months prior to screening and willing to not smoke during the study duration
- Willing and able to complete protocol required study follow-up assessments and procedures
- Fit for thoracoscopy under general anaesthesia (surgical and anaesthetic assessment)
Key exclusion criteria (11 listed)
- Fissure completeness <90% on pre EBLVR StratX (i.e less than 10% of fissure to be divided)
- Chartis positive for collateral ventilation or not performed/not satisfactory at initial EBLVR
- Quantitative perfusion of target lobe >25% of total on SPECT assessment.
- Previous lung surgery or pleurodesis on the target side for LVR.
- Clinically significant bronchiectasis -greater than 4 tablespoons mucus per day.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Surgical Lung Fissure DivisionThoracoscopic surgical division of interlobar fissure, in patients who did not achieve Lung Volume Reduction following Endobronchial Valve insertion. Standard thoracoscopic approach under general anaesthetic, as per individual surgeon preference or practice. Fissure identified and surgical division with mechanical stapler performed. | Procedure or surgery | Surgical Fissure Division |
Primary outcome
Number of patients recruited
Time frame: 18 months
At least 15 patients recruited into the trial over 18 months
Number of patients where surgical division of inter-lobar fissure can be successfully completed
Time frame: Through study completion (18 months)
Division of inter-lobar fissure can be completed in 90% of the patients enrolled
Number of patients who experience serious adverse events as a result of the intervention
Time frame: Through study completion (18 months)
Number of patients who experience serious adverse events as a result of the intervention
2 secondary outcomes
Target lobar collapse
Time frame: Through study completion (18 months)
Costs
Time frame: Through study completion (18 months)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
- Background: PubMed 36454166Magge A, Kent MS, Ospina-Delgado D, Swenson KE, Parikh MS, Zhang C, Gangadharan SP, Majid A. Robotic-assisted Fissure Completion for Lung Volume Reduction with Endobronchial Valves. Ann Am Thorac Soc. 2022 Dec;19(12):2087-2090. doi: 10.1513/AnnalsATS.202204-308CC. No abstract available.
- Background: PubMed 35940665Shafiq M, Polhemus E, Perkins R, Forth V, Marshall MB. Bilateral Bronchoscopic Lung Volume Reduction After Surgical Fissure Completion. Chest. 2022 Aug;162(2):e73-e75. doi: 10.1016/j.chest.2022.02.005.
- Background: PubMed 31436607Majid A, Kheir F, Alape D, Chee A, Parikh M, DeVore L, Agnew A, Gangadharan S. Combined Thoracoscopic Surgical Stapling and Endobronchial Valve Placement For Lung Volume Reduction With Incomplete Lobar Fissures: An Experimental Pilot Animal Study. J Bronchology Interv Pulmonol. 2020 Apr;27(2):128-134. doi: 10.1097/LBR.0000000000000617.
Related trials for Chronic Obstructive Pulmonary Disease (COPD)
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 1
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Surgical Lung Fissure Division in people with Chronic Obstructive Pulmonary Disease (COPD) and Emphysema, run by Rocco Bilancia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rocco Bilancia, MD (0141 951 5660, rocco.bilancia@gjnh.scot.nhs.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients recruited (time frame: 18 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07682168, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.